Park Square has placed David Moller, MD, as Chief Scientific Officer at Poxel SA.
| less than a minute read
Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer
Get in touch
Get in touch
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the appointment of David E. Moller, MD, as Chief Scientific Officer (CSO).
Get in touch
Get in touch
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-29-16-59-13-899-6abbee61460fb9469a25b973.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-10-21-12-53-31-969-6ad8b5cb057433a11d528afb.jpg)
/Passle/58a5cb8db00e8110e83aa395/SearchServiceImages/2026-10-19-20-59-27-876-6ad684af780cfbe7accbf179.jpg)
